Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
British Journal of Clinical Pharmacology|February 6, 2020
A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologicsAnne Bellon, Jessie Wang, Andrej Skerjanec, et al.Human Vaccines & Immunotherapeutics|February 17, 2026
Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation studyIsabel Leroux-Roels, Ilse De Coster, Alberto M Borobia, et al.Vaccine: X|May 3, 2023
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189]Xavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, et al.Vaccine: X|July 6, 2022
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized studyXavier Sáez-Llorens, Claudio Lanata, Elaine Aranguren, et al.Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.Human Vaccines & Immunotherapeutics|October 18, 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation studyBrandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, et al.Journal for Immunotherapy of Cancer|February 10, 2019
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancerAlexandros Papachristofilou, Madeleine M Hipp, Ute Klinkhardt, et al.Journal of Virology|October 24, 2014
Clonal evolution of CD8+ T cell responses against latent viruses: relationship among phenotype, localization, and functionEster B M Remmerswaal, Paul L Klarenbeek, Nuno L Alves, et al.Journal for Immunotherapy of Cancer|February 4, 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinomaThomas Eigentler, Ioannis Thomas, Igor Samoylenko, et al.Pageof 2